Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented IDH1R132-mutant tumors
ECOG performance status ≤ 2
You may not be if
Patients who have received prior treatment with a mutant-specific IDH1 inhibitor (with the exception of glioma patients)
Medical conditions that would prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures such as the presence of other clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological disease.
Acute Promyelocytic Leukemia
Women who are pregnant or lactating
Other protocol-defined Inclusion/Exclusion may apply
